chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 59.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Fatigue, Full blood count, Metabolic function test, Mononucleosis heterophile test, Night sweats
Clinical narrative: Chills; Night sweats; bodyaches; Fatigue; Low grade fever; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the arm left on 07Apr2021 at 16:15(at the age of 59-years-old) as a single dose for COVID-19 immunisation. The medical history included allergy to sulfa. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received unspecified medications within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EP7534) via an unspecified route of administration in the left arm on 17Mar2021 at 16:15 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. On 08Apr2021 at 10:00, the patient experienced chills, night sweats, body aches, fatigue and low grade fever. On 12Apr2021, the patient underwent SARS-CoV-2 test and the result was negative. The patient also underwent unspecified tests on an unknown date. The adverse events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of reported events which include treatment with NSAIDs. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events chills, night sweats, body aches, fatigue and low grade fever were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Oropharyngeal pain, Pain, Pyrexia, Rheumatoid factor, Urine analysis
Clinical narrative: Chills; Night sweats; bodyaches; Fatigue; Low grade fever; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the arm left on 07Apr2021 at 16:15(at the age of 59-years-old) as a single dose for COVID-19 immunisation. The medical history included allergy to sulfa. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received unspecified medications within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EP7534) via an unspecified route of administration in the left arm on 17Mar2021 at 16:15 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. On 08Apr2021 at 10:00, the patient experienced chills, night sweats, body aches, fatigue and low grade fever. On 12Apr2021, the patient underwent SARS-CoV-2 test and the result was negative. The patient also underwent unspecified tests on an unknown date. The adverse events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of reported events which include treatment with NSAIDs. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events chills, night sweats, body aches, fatigue and low grade fever were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Chills, Fatigue, Night sweats, Pain, Pyrexia
Clinical narrative: Chills; Night sweats; bodyaches; Fatigue; Low grade fever; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the arm left on 07Apr2021 at 16:15(at the age of 59-years-old) as a single dose for COVID-19 immunisation. The medical history included allergy to sulfa. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received unspecified medications within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EP7534) via an unspecified route of administration in the left arm on 17Mar2021 at 16:15 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. On 08Apr2021 at 10:00, the patient experienced chills, night sweats, body aches, fatigue and low grade fever. On 12Apr2021, the patient underwent SARS-CoV-2 test and the result was negative. The patient also underwent unspecified tests on an unknown date. The adverse events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of reported events which include treatment with NSAIDs. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events chills, night sweats, body aches, fatigue and low grade fever were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: SARS-CoV-2 test
Clinical narrative: Chills; Night sweats; bodyaches; Fatigue; Low grade fever; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the arm left on 07Apr2021 at 16:15(at the age of 59-years-old) as a single dose for COVID-19 immunisation. The medical history included allergy to sulfa. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received unspecified medications within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EP7534) via an unspecified route of administration in the left arm on 17Mar2021 at 16:15 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. On 08Apr2021 at 10:00, the patient experienced chills, night sweats, body aches, fatigue and low grade fever. On 12Apr2021, the patient underwent SARS-CoV-2 test and the result was negative. The patient also underwent unspecified tests on an unknown date. The adverse events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of reported events which include treatment with NSAIDs. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events chills, night sweats, body aches, fatigue and low grade fever were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Lymph node pain, Lymphadenopathy
Clinical narrative: Swollen and painful lymph nodes in the left armpit area; Swollen and painful lymph nodes in the left armpit area; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 22Apr2021 at 13:30 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history was reported as not applicable. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medication included cetirizine hydrochloride (ZYRTEC ALLERGY) from 20Apr2021 at 23:30 taken for an unknown indication and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the left arm on 31Mar2021 at 12:30 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. The patient previously received paracetamol; oxycodone hydrochloride; oxycodone terephthalate (PERCOCET) taken for an unknown indication and experienced drug allergy. On 23Apr2021 at 08:00, the patient had swollen and painful lymph nodes in the left armpit area. The swelling and pain occurred approximately 18 hours later. It had been 3 days with the swelling and painful lymph nodes (at the time of this report). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events swollen and painful lymph nodes in the left armpit area was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 62.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Rash
Clinical narrative: Rash on both inner forearms; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 15Apr2021 at 18:45 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included olmesartan (MANUFACTURER UNKNOWN) and curcuma longa rhizome (TURMERIC); both for an unknown indication from an unknown date and unknown if ongoing. On 16Apr2021 at 11:00, the patient experienced rash on both inner forearms. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the event rash on both inner forearms was resolved on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Burning sensation, Injection site rash, Rash pruritic
Clinical narrative: Rash; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the left arm on 14Apr2021 at 10:00 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received concomitant medications within 2 weeks of vaccinations which was unspecified. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the right arm on 24Mar2021 at 10:00 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. On 17Apr2021, the patient experienced rash. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event rash was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Rash
Clinical narrative: Rash; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the left arm on 14Apr2021 at 10:00 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received concomitant medications within 2 weeks of vaccinations which was unspecified. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the right arm on 24Mar2021 at 10:00 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. On 17Apr2021, the patient experienced rash. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event rash was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Blister, Pruritus, Rash, Skin burning sensation
Clinical narrative: Rash; This is a spontaneous report from a contactable consumer (patient). A 57-years-old male patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, lot number: EW0153) via an unspecified route of administration, administered in arm left on 14Apr2021 at 10:00 AM (age at the time of vaccination was 57-years-old) as DOSE 2, SINGLE for COVID-19 immunisation. Facility type vaccine was other, the patient did not take other vaccine in four weeks. Patient had no Covid prior vaccination and was not Covid tested post vaccination. The patient's medical history included Shellfish from an unknown date and unknown if ongoing. The patient took other medications in two weeks. Historical vaccine included bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, lot number: ER2613) via an unspecified route of administration, administered in arm left on 24Mar2021 at 10:00 AM (age at time of vaccination was 57-years-old) as DOSE 1, SINGLE for COVID-19 immunisation. On 23Apr2021, the patient experienced rash. No treatment was taken for adverse event rash. The outcome of the event was not recovered.  Follow-up attempts are completed. No further information was expected.
Age: 57.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Rash
Clinical narrative: Rash; This is a spontaneous report from a contactable consumer (patient). A 57-years-old male patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, lot number: EW0153) via an unspecified route of administration, administered in arm left on 14Apr2021 at 10:00 AM (age at the time of vaccination was 57-years-old) as DOSE 2, SINGLE for COVID-19 immunisation. Facility type vaccine was other, the patient did not take other vaccine in four weeks. Patient had no Covid prior vaccination and was not Covid tested post vaccination. The patient's medical history included Shellfish from an unknown date and unknown if ongoing. The patient took other medications in two weeks. Historical vaccine included bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, lot number: ER2613) via an unspecified route of administration, administered in arm left on 24Mar2021 at 10:00 AM (age at time of vaccination was 57-years-old) as DOSE 1, SINGLE for COVID-19 immunisation. On 23Apr2021, the patient experienced rash. No treatment was taken for adverse event rash. The outcome of the event was not recovered.  Follow-up attempts are completed. No further information was expected.
Age: 30.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Back pain, Headache, Injection site pain
Clinical narrative: Soreness in left arm; Headache; Upper back pain; This is a spontaneous report from a non-contactable consumer, the patient. A 30-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 25Apr2021 at 11:00 (at the age of 30-year-old) as a single dose for COVID-19 immunisation. Medical history included celiac disease and gluten intolerance. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Concomitant medications included sertraline hydrochloride (ZOLOFT), bupropion hydrochloride (WELLBUTRIN), ethinylestradiol, etonogestrel (NUVARING) and fexofenadine hydrochloride (ALLEGRA) for unknown indications, from unknown start dates and unknown if on going. On 25Apr2021 at 17:00, the patient experienced soreness in left arm, headache and upper back pain. No therapeutic measures were taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events soreness in left arm, headache and upper back pain was not recovered at the time of report.   No follow-up attempts are possible. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Back pain, Headache, Pain in extremity
Clinical narrative: Soreness in left arm; Headache; Upper back pain; This is a spontaneous report from a non-contactable consumer, the patient. A 30-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 25Apr2021 at 11:00 (at the age of 30-year-old) as a single dose for COVID-19 immunisation. Medical history included celiac disease and gluten intolerance. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Concomitant medications included sertraline hydrochloride (ZOLOFT), bupropion hydrochloride (WELLBUTRIN), ethinylestradiol, etonogestrel (NUVARING) and fexofenadine hydrochloride (ALLEGRA) for unknown indications, from unknown start dates and unknown if on going. On 25Apr2021 at 17:00, the patient experienced soreness in left arm, headache and upper back pain. No therapeutic measures were taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events soreness in left arm, headache and upper back pain was not recovered at the time of report.   No follow-up attempts are possible. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Hypoaesthesia oral
Clinical narrative: 30 minutes after receiving the injection, I experienced lip and tongue numbness, which lasted approximately 5 hours; 30 minutes after receiving the injection, I experienced lip and tongue numbness, which lasted approximately 5 hours; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0172) via an unspecified route of administration in the left arm on 25Apr2021 at 10:30 (at the age of 60-year-old) as a single dose for COVID-19 immunisation. Medical history included allergy to shellfish. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0151) via an unspecified route of administration in the left arm on 03Apr2021 at 14:30 (at the age of 60-year-old) as a single dose for COVID-19 immunisation. On 25Apr2021 at 11:00, 30 minutes after receiving the injection, the patient experienced lip and tongue numbness, which lasted approximately 5 hours. The events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. No therapeutic measures taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events lip and tongue numbness, which lasted approximately 5 hours was recovered on 25Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 72.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Dyspnoea, Loss of personal independence in daily activities, Pain, Pulmonary pain
Clinical narrative: aching lungs; heavy breathing required to move forward; This is a spontaneous report from a contactable consumer, the patient. A 72-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9266) via an unspecified route of administration in the left arm on 28Feb2021 at 14:00 (at the age of 72-year-old) as a single dose for COVID-19 immunisation. Medical history included cardiovascular challenges (unspecified cardiovascular disorder). The patient did not have any known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included amlodipine (MANUFACTURER UNKNOWN) and acetylsalicylic acid (ASPIRIN) for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 28Feb2021 at 22:00, after the second dose of vaccination, the patient experienced aching lungs with not much pain but quiet aching for 3 to 4 days. At that point, the patient's breathing function was not fully returned. It was reported that the patient's breathing was off 15 to 20 percentage, which impacted the patient's daily life when exerting but without gasping and required heavy breathing to move forward. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events aching lungs and heavy breathing required to move forward were recovered with sequelae on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 72.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Hyperventilation, Pulmonary pain
Clinical narrative: aching lungs; heavy breathing required to move forward; This is a spontaneous report from a contactable consumer, the patient. A 72-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9266) via an unspecified route of administration in the left arm on 28Feb2021 at 14:00 (at the age of 72-year-old) as a single dose for COVID-19 immunisation. Medical history included cardiovascular challenges (unspecified cardiovascular disorder). The patient did not have any known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included amlodipine (MANUFACTURER UNKNOWN) and acetylsalicylic acid (ASPIRIN) for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 28Feb2021 at 22:00, after the second dose of vaccination, the patient experienced aching lungs with not much pain but quiet aching for 3 to 4 days. At that point, the patient's breathing function was not fully returned. It was reported that the patient's breathing was off 15 to 20 percentage, which impacted the patient's daily life when exerting but without gasping and required heavy breathing to move forward. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events aching lungs and heavy breathing required to move forward were recovered with sequelae on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Erythema, Fatigue, Headache, Pruritus, Skin warm
Clinical narrative: Itchy rash; felt like I on fire neck arms legs back and worse on neck.; Severe Headache; could not open my eyes; extreme fatigue; lightheadedness; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the arm left on 23Apr2021 at 14:30 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Medical history included gastric bypass, anemia, ulcers, hernia, C-sections, gluten intolerance and latex allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included gabapentin (MANUFACTURER UNKNOWN), escitalopram oxalate (LEXAPRO) and colecalciferol (VITAMIN D3); all taken for unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the arm left on 02Apr2021 at 14:30 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. On 25Apr2021, at 23:00 the patient experienced itchy rash felt like she was on fire neck, arms, legs, back and worse on neck, severe headache could not open her eyes, extreme fatigue and lightheadedness. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. On 04Mar2021, the patient underwent nasal swab, SARS-CoV-2 test and the result was negative. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events itchy rash, felt like the she was on fire neck arms, legs, back and worse on neck, severe headache could not open her eyes, extreme fatigue and lightheadedness were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Burning sensation, Dizziness, Eyelid function disorder, Fatigue, Headache
Clinical narrative: Itchy rash; felt like I on fire neck arms legs back and worse on neck.; Severe Headache; could not open my eyes; extreme fatigue; lightheadedness; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the arm left on 23Apr2021 at 14:30 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Medical history included gastric bypass, anemia, ulcers, hernia, C-sections, gluten intolerance and latex allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included gabapentin (MANUFACTURER UNKNOWN), escitalopram oxalate (LEXAPRO) and colecalciferol (VITAMIN D3); all taken for unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the arm left on 02Apr2021 at 14:30 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. On 25Apr2021, at 23:00 the patient experienced itchy rash felt like she was on fire neck, arms, legs, back and worse on neck, severe headache could not open her eyes, extreme fatigue and lightheadedness. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. On 04Mar2021, the patient underwent nasal swab, SARS-CoV-2 test and the result was negative. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events itchy rash, felt like the she was on fire neck arms, legs, back and worse on neck, severe headache could not open her eyes, extreme fatigue and lightheadedness were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Rash pruritic, SARS-CoV-2 test
Clinical narrative: Itchy rash; felt like I on fire neck arms legs back and worse on neck.; Severe Headache; could not open my eyes; extreme fatigue; lightheadedness; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the arm left on 23Apr2021 at 14:30 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Medical history included gastric bypass, anemia, ulcers, hernia, C-sections, gluten intolerance and latex allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included gabapentin (MANUFACTURER UNKNOWN), escitalopram oxalate (LEXAPRO) and colecalciferol (VITAMIN D3); all taken for unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the arm left on 02Apr2021 at 14:30 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. On 25Apr2021, at 23:00 the patient experienced itchy rash felt like she was on fire neck, arms, legs, back and worse on neck, severe headache could not open her eyes, extreme fatigue and lightheadedness. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. On 04Mar2021, the patient underwent nasal swab, SARS-CoV-2 test and the result was negative. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events itchy rash, felt like the she was on fire neck arms, legs, back and worse on neck, severe headache could not open her eyes, extreme fatigue and lightheadedness were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Decreased appetite, Diarrhoea, Fatigue, Pyrexia, Vomiting
Clinical narrative: Moderate to severe vomiting; Moderate to severe vomiting and diarrhea; fever for several hours; 2-3 days of no appetite; Moderate to severe fatigue; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 02Apr2021 at 12:30 (at the age of 49-year-old), as a single dose for COVID-19 immunisation. Medical history included mild hypertension and mild acid reflux. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included loratadine (MANUFACTURER UNKNOWN), famotidine (MANUFACTURER UNKNOWN), hydrochlorothiazide, lisinopril dihydrate (PRINZIDE) and unspecified multivitamin, all for an unknown indication from an unknown date and unknown if ongoing. On 03Apr2021 at 18:00, the patient experienced moderate to severe vomiting and diarrhea with fever for several hours, followed by 2-3 days of no appetite and moderate to severe fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care.  Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events moderate to severe vomiting, moderate to severe diarrhea, fever, no appetite and moderate to severe fatigue was resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Asthenia, Atrial flutter, Axillary pain, Fatigue
Clinical narrative: After 2nd Shot 1-5 days swelling and rash; After 2nd Shot 1-5 days swelling and rash.; Pain in arm at injection side; Day 3-4 Throbbing leg - felt arteryflutter; Day 3-4 Throbbing leg - felt artery flutter; 1-12 days recurring headache; 3-18 days pain in shoulder and armpitnear injection site; 3-18 days pain in shoulder and armpitnear injection site; Day 12-18 swelling in hand; Day 2-18 - extreme fatigue; Day 2-18 - higher blood pressure; Day 4-18  Nausea and forgetfulness; Day 4-18  Nausea and forgetfulness; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0152) via an unspecified route of administration in the right arm on 06Apr2021 at 11:30 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. Medical history included cancer, had lower platelets during cancer treatment and allergic to latex. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN) for unknown indications from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0205) via an unspecified route of administration in the left arm on 16Mar2021 at 11:00 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. After 2nd Shot on an unknown date in Apr2021, on days 1-5, the patient experienced swelling, rash, pain in arm at injection side. On days 3-4, the patient had throbbing leg-felt artery flutter. On days 1-12, the patient had recurring headache. On days 3-18, the patient experienced pain in shoulder and armpit near injection site. On days 12-18, the patient had swelling in hand and on days 2-18 felt extreme fatigue. On days 2-18, the patient had higher blood pressure and on days 4-18 nausea and forgetfulness. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events swelling and rash, pain in arm at injection side, throbbing leg, felt artery flutter, recurring headache, pain in shoulder and armpit near injection site, extreme fatigue, higher blood pressure, nausea, forgetfulness and swelling in hand were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Headache, Hypertension, Injection site pain, Injection site rash, Injection site swelling
Clinical narrative: After 2nd Shot 1-5 days swelling and rash; After 2nd Shot 1-5 days swelling and rash.; Pain in arm at injection side; Day 3-4 Throbbing leg - felt arteryflutter; Day 3-4 Throbbing leg - felt artery flutter; 1-12 days recurring headache; 3-18 days pain in shoulder and armpitnear injection site; 3-18 days pain in shoulder and armpitnear injection site; Day 12-18 swelling in hand; Day 2-18 - extreme fatigue; Day 2-18 - higher blood pressure; Day 4-18  Nausea and forgetfulness; Day 4-18  Nausea and forgetfulness; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0152) via an unspecified route of administration in the right arm on 06Apr2021 at 11:30 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. Medical history included cancer, had lower platelets during cancer treatment and allergic to latex. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN) for unknown indications from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0205) via an unspecified route of administration in the left arm on 16Mar2021 at 11:00 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. After 2nd Shot on an unknown date in Apr2021, on days 1-5, the patient experienced swelling, rash, pain in arm at injection side. On days 3-4, the patient had throbbing leg-felt artery flutter. On days 1-12, the patient had recurring headache. On days 3-18, the patient experienced pain in shoulder and armpit near injection site. On days 12-18, the patient had swelling in hand and on days 2-18 felt extreme fatigue. On days 2-18, the patient had higher blood pressure and on days 4-18 nausea and forgetfulness. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events swelling and rash, pain in arm at injection side, throbbing leg, felt artery flutter, recurring headache, pain in shoulder and armpit near injection site, extreme fatigue, higher blood pressure, nausea, forgetfulness and swelling in hand were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Memory impairment, Nausea, Peripheral swelling
Clinical narrative: After 2nd Shot 1-5 days swelling and rash; After 2nd Shot 1-5 days swelling and rash.; Pain in arm at injection side; Day 3-4 Throbbing leg - felt arteryflutter; Day 3-4 Throbbing leg - felt artery flutter; 1-12 days recurring headache; 3-18 days pain in shoulder and armpitnear injection site; 3-18 days pain in shoulder and armpitnear injection site; Day 12-18 swelling in hand; Day 2-18 - extreme fatigue; Day 2-18 - higher blood pressure; Day 4-18  Nausea and forgetfulness; Day 4-18  Nausea and forgetfulness; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0152) via an unspecified route of administration in the right arm on 06Apr2021 at 11:30 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. Medical history included cancer, had lower platelets during cancer treatment and allergic to latex. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN) for unknown indications from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0205) via an unspecified route of administration in the left arm on 16Mar2021 at 11:00 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. After 2nd Shot on an unknown date in Apr2021, on days 1-5, the patient experienced swelling, rash, pain in arm at injection side. On days 3-4, the patient had throbbing leg-felt artery flutter. On days 1-12, the patient had recurring headache. On days 3-18, the patient experienced pain in shoulder and armpit near injection site. On days 12-18, the patient had swelling in hand and on days 2-18 felt extreme fatigue. On days 2-18, the patient had higher blood pressure and on days 4-18 nausea and forgetfulness. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events swelling and rash, pain in arm at injection side, throbbing leg, felt artery flutter, recurring headache, pain in shoulder and armpit near injection site, extreme fatigue, higher blood pressure, nausea, forgetfulness and swelling in hand were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Atrial flutter, Axillary pain, Blood pressure measurement, Fatigue
Clinical narrative: After 2nd Shot 1-5 days swelling and rash; After 2nd Shot 1-5 days swelling and rash.; Pain in arm at injection side; Day 3-4 Throbbing leg - felt arteryflutter; Day 3-4 Throbbing leg - felt artery flutter; 1-12 days recurring headache; 3-18 days pain in shoulder and armpitnear injection site; 3-18 days pain in shoulder and armpitnear injection site; Day 12-18 swelling in hand; Day 2-18 - extreme fatigue; Day 2-18 - higher blood pressure; Day 4-18  Nausea and forgetfulness; Day 4-18  Nausea and forgetfulness; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0152) via an unspecified route of administration in the right arm on 06Apr2021 at 11:30 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. Medical history included cancer, had lower platelets during cancer treatment and allergic to latex. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN) for unknown indications from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0205) via an unspecified route of administration in the left arm on 16Mar2021 at 11:00 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. After 2nd Shot on an unknown date in Apr2021, on days 1-5, the patient experienced swelling, rash, pain in arm at injection side. On days 3-4, the patient had throbbing leg-felt artery flutter. On days 1-12, the patient had recurring headache. On days 3-18, the patient experienced pain in shoulder and armpit near injection site. On days 12-18, the patient had swelling in hand and on days 2-18 felt extreme fatigue. On days 2-18, the patient had higher blood pressure and on days 4-18 nausea and forgetfulness. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events swelling and rash, pain in arm at injection side, throbbing leg, felt artery flutter, recurring headache, pain in shoulder and armpit near injection site, extreme fatigue, higher blood pressure, nausea, forgetfulness and swelling in hand were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Headache, Hypertension, Memory impairment, Nausea, Pain in extremity
Clinical narrative: After 2nd Shot 1-5 days swelling and rash; After 2nd Shot 1-5 days swelling and rash.; Pain in arm at injection side; Day 3-4 Throbbing leg - felt arteryflutter; Day 3-4 Throbbing leg - felt artery flutter; 1-12 days recurring headache; 3-18 days pain in shoulder and armpitnear injection site; 3-18 days pain in shoulder and armpitnear injection site; Day 12-18 swelling in hand; Day 2-18 - extreme fatigue; Day 2-18 - higher blood pressure; Day 4-18  Nausea and forgetfulness; Day 4-18  Nausea and forgetfulness; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0152) via an unspecified route of administration in the right arm on 06Apr2021 at 11:30 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. Medical history included cancer, had lower platelets during cancer treatment and allergic to latex. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN) for unknown indications from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0205) via an unspecified route of administration in the left arm on 16Mar2021 at 11:00 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. After 2nd Shot on an unknown date in Apr2021, on days 1-5, the patient experienced swelling, rash, pain in arm at injection side. On days 3-4, the patient had throbbing leg-felt artery flutter. On days 1-12, the patient had recurring headache. On days 3-18, the patient experienced pain in shoulder and armpit near injection site. On days 12-18, the patient had swelling in hand and on days 2-18 felt extreme fatigue. On days 2-18, the patient had higher blood pressure and on days 4-18 nausea and forgetfulness. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events swelling and rash, pain in arm at injection side, throbbing leg, felt artery flutter, recurring headache, pain in shoulder and armpit near injection site, extreme fatigue, higher blood pressure, nausea, forgetfulness and swelling in hand were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.